Status:
COMPLETED
Plasma Citrulline: A Marker for Monitoring & Quantifying Radiation-Induced Small Bowel Toxicity
Lead Sponsor:
Asan Medical Center
Conditions:
Diarrhea
Anorexia
Eligibility:
All Genders
20+ years
Phase:
NA
Brief Summary
Small bowel irradiation results in epithelial cell loss and consequently impairs function and metabolism. A metabolic end product of small bowel enterocytes is plasma citrulline. The investigators eva...
Eligibility Criteria
Inclusion
- Histologically confirmed cancer patients
- Appropriate liver, renal, and bone marrow function for radiotherapy
- Willing to provide informed written consent
- At least 20 years old
Exclusion
- prior abdominopelvic radiation therapy or chemotherapy or abdominal surgery
- Any contraindication to radiotherapy (i.e. Severe connective tissue disorder, etc.)
- Prior or simultaneous history of other malignancy
- On medication for small bowel disease or CTCAE 4.0 Grade 1 or higher toxicity before radiation
- Any treatment delay more than 1 week during radiotherapy
- No radiotherapy due to any other reason except small bowel toxicity
Key Trial Info
Start Date :
April 1 2013
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
December 1 2014
Estimated Enrollment :
49 Patients enrolled
Trial Details
Trial ID
NCT01849107
Start Date
April 1 2013
End Date
December 1 2014
Last Update
January 13 2020
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Asan Medical Center
Seoul, South Korea, 138-736